
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GSK | London | GBP | Real-time | |
GSKl | BATS Europe | GBP | Delayed | |
GSK | NYSE | USD | Real-time | |
GLAXF | OTC Markets | USD | Delayed | |
GSKN | Mexico | MXN | Delayed | |
GSKy | Frankfurt | EUR | Delayed | |
GSK | Frankfurt | EUR | Delayed | |
GSK | TradeGate | EUR | Delayed | |
GS71 | Xetra | EUR | Delayed | |
GSK | Buenos Aires | ARS | Delayed |
Period Ending: | 2022 30/06 |
2022 31/03 |
2021 30/06 |
2021 31/03 |
||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 6929 | 7190 | 5838 | 5155 | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
Cost of Revenue, Total | 2145 | 2690 | 1683 | 1627 | ||||||||||||||||||||||||||||||
Gross Profit | 4784 | 4500 | 4155 | 3528 | ||||||||||||||||||||||||||||||
Total Operating Expenses | 5220 | 5482 | 4356 | 3998 | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
Operating Income | 1709 | 1708 | 1482 | 1157 | ||||||||||||||||||||||||||||||
Interest Income (Expense), Net Non-Operating | - | - | - | - | ||||||||||||||||||||||||||||||
Gain (Loss) on Sale of Assets | - | - | -36 | - | ||||||||||||||||||||||||||||||
Other, Net | 813 | -386 | 448 | 123 | ||||||||||||||||||||||||||||||
Net Income Before Taxes | 896 | 2094 | 1070 | 1034 | ||||||||||||||||||||||||||||||
Provision for Income Taxes | 150 | 323 | -201 | 155 | ||||||||||||||||||||||||||||||
Net Income After Taxes | 746 | 1771 | 1271 | 879 | ||||||||||||||||||||||||||||||
Minority Interest | 6266 | - | - | - | ||||||||||||||||||||||||||||||
Equity In Affiliates | - | - | - | - | ||||||||||||||||||||||||||||||
U.S GAAP Adjustment | - | - | - | - | ||||||||||||||||||||||||||||||
Net Income Before Extraordinary Items | 706 | 1496 | 1214 | 799 | ||||||||||||||||||||||||||||||
Total Extraordinary Items | 132 | 306 | 181 | 274 | ||||||||||||||||||||||||||||||
Net Income | 838 | 1802 | 1395 | 1073 | ||||||||||||||||||||||||||||||
Total Adjustments to Net Income | -132 | -306 | -181 | -274 | ||||||||||||||||||||||||||||||
Income Available to Common Excluding Extraordinary Items | 706 | 1496 | 1214 | 799 | ||||||||||||||||||||||||||||||
Dilution Adjustment | 130.86 | 305.1 | 179.56 | 275.47 | ||||||||||||||||||||||||||||||
Diluted Net Income | 707.14 | 1496.9 | 1215.44 | 797.53 | ||||||||||||||||||||||||||||||
Diluted Weighted Average Shares | 4064 | 4054 | 4038 | 4030 | ||||||||||||||||||||||||||||||
Diluted EPS Excluding Extraordinary Items | 0.174 | 0.369 | 0.301 | 0.198 | ||||||||||||||||||||||||||||||
DPS - Common Stock Primary Issue | 0.162 | 0.175 | 0.238 | 0.238 | ||||||||||||||||||||||||||||||
Diluted Normalized EPS | 0.225 | 0.165 | 0.189 | 0.132 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review